RNA-seq Reveals the Overexpression of IGSF9 in Endometrial Cancer

Table 2

IGSF9 expression and survival correlation in TCGA RNA-seq dataset.

Abbrev.	Cancer type	Sample size^(1)	Expression level^(2)	Overall survival^(3)
BLCA	Bladder urothelial carcinoma	Normal (); Tumor ()	Up	-
BRCA	Breast invasive carcinoma	Normal (); Tumor ()	Up	-
CESC	Cervical squamous cell carcinoma and endocervical adenocarcinoma	Normal (); Tumor ()	Up	-
CHOL	Cholangiocarcinoma	Normal (); Tumor ()	Up	-
COAD	Colon adenocarcinoma	Normal (); Tumor ()	Down	-
HNSC	Head and neck squamous cell carcinoma	Normal (); Tumor ()	Up	-
LGG	Brain lower grade glioma	Grade II (); Grade III ()	-	Yes
LUSC	Lung squamous cell carcinoma	Normal (); Tumor ()	Up	-
READ	Rectum adenocarcinoma	Normal (); Tumor ()	Down	-
SKCM	Skin cutaneous melanoma	Normal (); Tumor ()	-	Yes
THCA	Thyroid carcinoma	Normal (); Tumor ()	Up	-
THYM	Thymoma	Normal (); Tumor ()	-	Yes
UCEC	Uterine corpus endometrial cancer	Normal (); Tumor ()	Up	Yes

Notes. ⁽¹⁾The number of normal versus tumor samples, except for LGG. ⁽²⁾“Up” or “Down” indicates significant expression level changes, tumor versus normal; dash indicates no significant change. ⁽³⁾Kaplan-Meier analysis; “Yes” indicates that higher expression of IGSF9 is related to poor overall survival.